Bild/Picture ®Thomas Ferber/Oncoletter

  • Oral Abstract Session - Pediatric Oncology
  • Poster Discussion Session - Pediatric Oncology

Oral Abstract Session - Pediatric Oncology

Abstract 10000: Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).

Presenter: Anna Rachel Keating Franklin

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10000

---------------------------------------------------------------------------------------------------------------------------

Abstract 10001: Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.

Presenter: Laura E. Hogan

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10001

---------------------------------------------------------------------------------------------------------------------------

Abstract: 10002: BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Presenter: Juliet Gray

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10002

---------------------------------------------------------------------------------------------------------------------------

Abstract 10003: A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.

Presenter: Sara Michele Federico

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10003

---------------------------------------------------------------------------------------------------------------------------

Abstract: 10004: Poverty, race, ethnicity, and survival among U.S. children with non-metastatic osteosarcoma treated on EURAMOS-1: A report from the Children’s Oncology Group.

Presenter: Lenka Anne Skaidrite Ilcisin

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10004

---------------------------------------------------------------------------------------------------------------------------

Abstract 10005: Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children’s Oncology Group clinical trials.

Presenter: Puja J Umaretiya

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10005

---------------------------------------------------------------------------------------------------------------------------

Abstract 10006: Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE).

Presenter: Pablo Berlanga

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10006

---------------------------------------------------------------------------------------------------------------------------

Abstract 10007: Late mortality and morbidity among adult survivors of childhood glioma treated over three decades: A report from the Childhood Cancer Survivor Study.

Presenter: Peter de Blank

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10007

---------------------------------------------------------------------------------------------------------------------------

Abstract: 10008: Joint effects of general population polygenic risk scores (PRS) and radiation treatment on subsequent neoplasm risk among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).

Presenter: Todd M. Gibson

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10008

---------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration

----------------------------------------------------------------------------------------------------------------------------

POSTER SESSION

Pediatric Oncology

https://meetings.asco.org/2022-asco-annual-meeting/14401?presentation=206937#206937

 

Poster Discussion Session - Pediatric Oncology

Abstract 10009: Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Presenter: Susan N. Chi | Poster: 224

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10009

------------------------------------------------------------------------------------------------------------------------

Abstract 10010: Matched external control analysis of event-free survival (EFS) in patients  with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.

Presenter: Javier E. Oesterheld | Poster: 225

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10010

------------------------------------------------------------------------------------------------------------------------

Abstract 10011: STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.

Presenter: Navin R. Pinto | Poster: 226

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10011

------------------------------------------------------------------------------------------------------------------------

Abstract 10012: Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.

Presenter: Zeinab A.M. Afify | Poster: 227

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10012

------------------------------------------------------------------------------------------------------------------------

Abstract: 10013: Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.

Presenter: Wendy B. London | Poster: 228

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10013

------------------------------------------------------------------------------------------------------------------------

Abstract 10014: Modifiable risk factors for late mortality among five-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Presenter: Stephanie B Dixon | Poster: 229

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10014

------------------------------------------------------------------------------------------------------------------------

Abstract 10015: Benefits, harms, and burden of colorectal cancer screening among childhood cancer survivors previously treated with abdominal-pelvic radiation.

Presenter: Jennifer M Yeh | Poster: 230

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10015

------------------------------------------------------------------------------------------------------------------------

Abstract 10016: Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.

Presenter: Panayiotis Vandris | Poster: 231

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10016

------------------------------------------------------------------------------------------------------------------------

Abstract 10017: Racial and ethnic differences in presentation and clinical outcomes for pediatric rhabdomyosarcoma (RMS).

Presenter: Princess Ekpo | Poster: 232

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10017

------------------------------------------------------------------------------------------------------------------------

Abstract 10018: Barriers to effective childhood cancer control in Kenya (BECK) study, 2019-2020: A mixed methods study in a national tertiary facility and 10 regional cancer treatment centers.

Presenter: Valerian Mwenda | Poster: 233

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10018

------------------------------------------------------------------------------------------------------------------------

Abstract 10019: Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies.

Presenter: Sarah Elizabeth Monick | Poster: 234

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10019

------------------------------------------------------------------------------------------------------------------------

Abstract 10020: Neuropathy and neurocognitive impairment in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.

Presenter: AnnaLynn Williams | Poster: 235

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10020

------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close